Add Company
Join Now

Todd Baumgartner Email

SVP, Global Regulatory Affairs, Pharmacovigilance and Biometrics . Ovid Therapeutics

New York, NY

Location

How to contact Todd Baumgartner

Join and see Todd's contact info for free!

Email

Phone

Current Roles

Ovid Therapeutics

Employees:
46
Revenue:
$214.1M
About
Ovid Therapeutics is a biopharmaceutical company focused exclusively on developing impactful medicines for patients and families living with rare neurological disorders. Ovid's drug candidate, OV101, is currently in development for the treatment of symptoms of Angelman syndrome and Fragile X syndrome. Ovid is also developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies. Ovid has initiated the Phase 2 STARS trial of OV101 in adults with Angelman syndrome and a Phase 1 trial in adolescents with Angelman and Fragile X syndrome to identify doses suitable for younger patients. Review our community guidelines: http://www.ovidrx.com/community-guidelines/
Ovid Therapeutics Address
441 9th Avenue
New York, NY
United States
Ovid Therapeutics Email

Past Companies

Ovid TherapeuticsSenior Vice President, Global Regulatory Affairs, Pharmacovigilance and Biometrics
Acorda Therapeutics, Inc.Senior Vice President, Regulatory Affairs and Clinical Operations
Purdue Pharma L.P.Chief Medical Officer - Vice President, Research and Development
www.growjo.com

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.